Equillium faces standard financial risks inherent to pre-revenue, clinical-stage biotechnology companies, including ongoing operating losses, a complete lack of traditional product sales revenue, and heavy reliance on external capital raising. While careful capital management extends its operational runway, the company remains vulnerable to high cash burn rates, clinical trial trial setbacks, and dilution risks from future equity offerings.